Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENECA: CAPTEM vs FOLFIRI in NEC G3
NCT03387592Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2017
- Primary completion
- Feb 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, temozolomide in neuroendocrine carcinoma (NEC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Mar 2017; status: terminated.
02
Drugs
capecitabinetemozolomide
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03387592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387592.